Susquehanna analyst Mehdi Hosseini maintains GLOBALFOUNDRIES (NASDAQ:GFS) with a Positive and raises the price target from $76 to $84.
Regenerative Medicine Firm Humacyte’s Bioengineered Tissue Shows Promise In Trauma Injuries
Humacyte Inc (NASDAQ: HUMA) released topline results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair, showing that the HAV had higher rates of patency and lower rates of amputation and infection than historic